medigraphic.com
Instituto Nacional de Salud Pública

2018, Número 6

<< Anterior Siguiente >>

salud publica mex 2018; 60 (6)


HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns

Bosch FX, Robles C

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 612-616
Archivo PDF: 515.02 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105:28-37. https://doi.org/10.1038/bjc.2011.185

  2. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16:1154-68. https://doi. org/10.1016/S1473-3099(16)30120-7

  3. Arbyn M, Haelens A, Desomer A, Verdoodt F, Thiry N, Francart J, et al. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening. KCE Reports 238. D/2015/10.273/17. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE), 2015 [cited 2018, July 13]. Available from: https://kce.fgov.be/sites/default/files/atoms/files/KCE__238_HPV_ DNA_Testing_Report2_.pdf

  4. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88-99. https://doi.org/10.1016/j. vaccine.2012.06.095

  5. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbny M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32. https://doi.org/10.1016/S0140-6736(13)62218-7

  6. European Medicines Agency. Cervarix. Human Papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). European Medicines Agency, 2016 [cited 2018 July 13]. Available from: https://www.ema.europa. eu/medicines/human/EPAR/cervarix

  7. European Medicines Agency. Gardasil. Human Papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed). European Medicines Agency, 2018 [cited 2018 July 13]. Available from: https://www.ema.europa.eu/ medicines/human/EPAR/gardasil

  8. European Medicines Agency. Gardasil 9. Human Papillomavirus 9-valent vaccine (recombinant, adsorbed). European Medicines Agency, 2018 [cited 2018 July 13]. Available from: https://www.ema.europa.eu/medicines/human/ EPAR/gardasil-9

  9. US Food & Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. Silver Spring, MD: FDA, 2018 [cited 2018, July 13]. Available from: https://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm

  10. de Sanjose S, Cortés X, Méndez C, Puig-Tintore L, Torné A, Roura E, et al. Age at sexual initiation and number of sexual partners in the female Spanish population Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol. 2008;140(2);234-40. https://doi.org/10.1016/j. ejogrb.2008.04.005

  11. Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano- Ponce E, Del Rosario-Raymundo MR, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138(10):2428-38. https://doi.org/10.1002/ijc.29971

  12. Hildesheim A, Herrero R, Wacholder S, Rodríguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-53. https://doi.org/10.1001/jama.298.7.743

  13. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. 2012;131(1):106-16. https://doi.org/10.1002/ijc.26362

  14. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018;41(4):329-46. https://doi.org/10.1007/s40264-017-0625-z

  15. Drolet M, Bénard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population- level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80. https://doi.org/10.1016/S1473-3099(14)71073-4

  16. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, et al. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016;58:211-9. https://doi.org/10.21149/spm.v58i2.7790

  17. Edgren G, Sparén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007;8(4):311-6. https://doi.org/10.1016/S1470-2045(07)70043-8

  18. Sikora AG, Morris LG, Sturgis EM. Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Arch Otolaryngol Head Neck Surg. 2009;135(4):402-5. https://doi.org/10.1001/archoto.2009.19

  19. Schiller JT, Davies P. Delivering on the prounise: HPV vaccines and cervical cancer. Nat Rev Microbiol. 2004;2:343-347. https://doi.org/10.1038/ nrmicro867

  20. Anttila A, Arbyn A, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al (eds). European Guidelines for Quality Assurance in Cervical Cancer Screening. second edition, Supplements. Luxembourg: Office for Official Publications of the European Union, 2015. https://doi.org/10.2875/859507

  21. Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhalta N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67-77. https://doi.org/10.1016/ S1470-2045(15)00414-3

  22. Kreimer AR, Struyf F, Del Rosario-Raymundo MW, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015;16(7):775-86. https://doi.org/10.1016/S1470-2045(15)00047-9

  23. Stanley M, Dull P. HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Vaccine. 2018;36(32):4759-60. https:// doi.org/10.1016/j.vaccine.2018.02.076

  24. Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13(2):119-32. https://doi.org/10.1038/nrclinonc. 2015.146




2020     |     www.medigraphic.com